U.S. markets closed

Inovio Pharmaceuticals, Inc. (INO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.14+0.39 (+5.03%)
At close: 4:00PM EDT
8.05 -0.09 (-1.11%)
After hours: 07:52PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close7.75
Open7.80
Bid8.07 x 4000
Ask8.10 x 2900
Day's Range7.68 - 8.15
52 Week Range5.81 - 19.00
Volume6,417,988
Avg. Volume4,616,153
Market Cap1.712B
Beta (5Y Monthly)0.62
PE Ratio (TTM)N/A
EPS (TTM)-0.75
Earnings DateNov 08, 2021 - Nov 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.22
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Inovio Pharmaceuticals, Inc.
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion. Pfizer also spends a leading amount on research and development, close to $8 billion annually. While Pfizer historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
    Rating
    Fair Value
    Economic Moat
    5 days agoMorningstar
View more
  • Investor's Business Daily

    Is Inovio Stock A Buy After Brazil OKs Phase 3 Test For Covid Vaccine?

    Is INO stock a buy after Brazil's national health agency granted Inovio permission to begin a Phase 2 and Phase 3 Covid vaccine test?

  • TheStreet.com

    Inovio Downgraded by BofA on Limited Covid Opportunity

    Company's COVID vaccine candidate has lower likely returns than other therapies with longer timelines, BofA said.

  • Motley Fool

    5 Stocks With 195% to 467% Upside, According to Wall Street

    If the high-water price target for each of the following five stocks were to come to fruition, shareholders would be looking at gains ranging from a low of 195% to as much as 467%. If you're "only" looking to triple your money, analyst Amit Dayal of H.C. Wainwright would suggest putting it to work in hydrogen fuel-cell solutions company Plug Power (NASDAQ: PLUG). Dayal's price target of $78 implies a cool 195% upside from where its shares closed this past weekend.